一年一度的J.P Morgan Healthcare Conference一直是享誉生物医药产业的全球战略风向标和项目对接交易的盛会。旧金山时间2020年1月12日，第38届J.P Morgan Healthcare Conference 会议期间，2020 China Focus 会议上，由誉衡生物独家赞助，Ginger Ding 女士（MyBioGate 投资分析全球总监）主持的路演专场中，数十家创新药物，医疗器械，医疗服务健康，生物医药产业全自动化，AI人工智能辅助新药研发等领域公司带来了精彩的演讲展示。
China Focus 路演专场从第一次推出，就受到了跨境平台合作上最为著名积极的龙头企业鼎力支持。恒瑞医药、FC Capital、 勃林格殷格翰、复星、江苏省产业技术研究院、步长医药的等企业大佬场场出席，可见China Focus 路演的影响力和效力满满。随着国内生物医药企业国际间合作越来越多，各类创新主体都有着独特的自身战略。个体优势，只有结合市场，集思广益，才能做出效益最大化的合作及选择，国际化合作将是未来全球药企发展的必然趋势。
China Focus 路演专场还专门请到了六位重量级嘉宾分享其成功海内外项目对接，融资等成功的经验。嘉宾们针对中美商业文化差异进行了深入交流讨论，大家一致认为：与中国企业打交道的方式越来越国际化、专业化、便利化，对中外商业互通接受度也越来越高，China Focus路演专场正在为更多的国内药企、国际药企、以及海内外投资机构提供更有深度的对接服务，并承担着真正意义上的“引路人”角色。
在随后的China Focus路演专场，依次进行项目展示（公司推广）的是誉衡生物、拜耳（中国）、挚盟医药、开拓药业（Kintor）、惠瑞生物、瑞顺生物、索元生物医药、剂泰医药、Maintect GmbH、Celsion、Targovax（OSE：TRVX）、Flow Pharma、Curevo Vaccine、Cerenetex、Dyadic International、Virometix、OncoGenesis、Strateos、Gero、VivaLNK、Canary Speech、TECLens、Erythra、Avotres等24家中外肿瘤、慢性乙型肝炎、中风、传染病疫苗、医疗物联网平台等业界生物技术和制药的翘楚公司。项目方对企业进行了全方位展示，并和慕名而来的投资人进行现场答疑与深度对接。
Company Presentation Reference:
1. Targovax
Goal: Activate immune system to inhibit cancer
Target: Lung cancer, melanoma
Method: Develop checkpoint inhibitor to activate immune system ➔ produce more T cells
Platform:
◆ Oncolytic virus ➔ To treat T cell targeting specific tumor
◆ Neoantigen vaccine
2.Flowpharma
Goal: To treat virtual disease, cancer
Target: Breast cancer/ Ebola/ cervical cancer
Platform:
◆ FlowVAX, a neoantigen cancer vaccine; high yield but low cost
◆ SEAPAC Delivery platform (cancer vaccines need a good delivery technology)
Strategy:
Virus in the targeted cells (APC) can recognize neopeptide ➔ produce cytokines ➔release and kill cancer cells.
FlowVAX Workflow (4 weeks total)
◆ Sequence cancer cell
◆ AI screen novel neoantigens
◆ In vitro confirmation
Key advantages:
◆ Each APC only recognize one neoantigen
◆ Intensive T cell activation
◆ Safer, cheaper
◆ No immune response
3. Cerenetex
Focuses: delay in stroke care; delayed treatment
Solutions: cerebral hemodynamics that produced by blood flow
Headphone could pick up acoustic signal produced by cerebral hemodynamics ➔ record➔cloud
Application: Reflect whether the stroke treatment is effective
4. Dyadic
Platform: C1 Fungal gene expression platform
C1: myoliophthna thermophila from alkaline soil in Russia
Advantages: High purity of target protein screted, low cost
Application: glycoengineering— C1 is better than yeast, faster, higher yield
5. Maintest
Target: wet age related-macular degeneration (WAMD)
Problem: ¼ patients shows no effect with current treatment
Strategy: anti-angiogenesis treatment via inhibition of VEGF
Stage: They have already developed the antibody AB125, and tested in vitro/ in vivo; confirmed in initial clinical trial.
Workplan:
1.5-2 years: develop kit
3-5 years: clinical trail
6. Zhimeng Biopharma
Target: 1. Anti-virus/ HBV; 2. CNS: epilepsy, pain, stroke
Pipeline:
HBV—Caspid inhibitor; RNA destabilizer; TLR8 agonist
Epilepsy — KCNQ 2/3 opener
Pain — KCNQ 2/3 opener
Stroke — PSD95 antagonist
7. Virometix
Platform:
◆ SVLP: synthetic virus-like particle (30nm)
◆ synthetic antigen mimetic (SAM)
8. Denovo Biopharma
Goal: Using AI driven method to treat schizophrenia, AD
Strategy: transform failed drugs into successful personalized medicine
From the drugs that fail in phase 3 ➔ search new markers ➔ modify the drug ➔ phase 3
9. Oncogenesis
Goal: To treat cervical cancer
Current situation: HPV DNA screen (not effective)
Strategy:
new protein biomarker –CerMark
iPap self-assembly collector à CerMark POC analyzer
Advantages:
Patients don’t need to return to clinic for Pap test
High specific; high sensitivity
10. Curevo Vaccine
Targeted diseases: shingles; chickenpox
Strategy: CRV101, a synthetic TLR4 agonist, already in phase 1, suitable for children and adults, not a live virus. Look for parterner, look for $20 million for funding
11. Suzhou Kintor Pharma
Target: cancer
Strategy: monotherapy
IPO preparation
12. Huirui Biopharma Company
Target: infectious disease, autoimmune disease, tumor, leukemia
Gap: current anti-flu medicine induces drug resistance
Products: BH103
Decrease lung cytokine levels
Not expect to induce drug resistance
13. Celsion
Platform: noval nanoparticle-based technology
◆ LTSL (lipidsome for delivery)— ThermoDOX
◆ Theroplas—GEN-1 immunotherapy
Using DNA plasmid coded for therapeutic protein as a drug
Milestone events:
Targeting hepatocellular carcinoma
ThermaDOX+ radio frequency ablation (RFA) ➔ expand the treatment zone ➔ survival time increase 2 years
14. WYZE Biotech
Target: acute myeloid leukemia (AML)
Platform: DNT cells (CD3+ CD4- CD8- cells)= double negative T cells ( DNT)
DNT cells are a novel therapy to target AML, effective in eliminating AML
15. Strateos
Goal: accelerating discovery
Platform: using AI, open access, fully-automated, programmable lab
Strategy: Automated chemical synthesis ➔ auto biotestingà product ➔ automated chemical synthesis
16. Gloria Bioscience
Products: GLS-010 fully anti-human PL-1 (naturally screened from transgenic rat platform)
Preliminary Results: Shows impressive antitumor activity when treated on cervical cancer
17. Avotres
Pipeline: 3 year development plan, exit by 2022
Strategy: Find a way to treat regulatory T cells (which can secrete cytokines)
Product: AVT002
18. Gero
Goal: drug discovery against complex diseases
Solution: “Deep phenotype”—model of disease progression with actionable biomarker from large unbiased human cohorts.
Machine learning
Ongoing: Using immune senescence, metabolic health, senescent cells burden as targets to develop anti-aging drugs.
19. Bayer
Right timing and Right places to develop the company in China.
Focus on: cardiovascular and cerebrovascular diseases; diabetes; respiratory disease; cancer; infectious disease
20. Viva LNK
Product: one small device can continuously measure blood pressure, respiration, ECG/HR, temperature, heart failure detection.
21. Canary Speech
Speech can reflect the central nervous system.
Strategy: identify more than 2000 biomarkers in language, to detect neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s’ disease.
22. Teclens
Products: Teclens, contains vitamin B2 + 375nm low intensity UV light in surgery.
Advantages: The lens move along with the eyeballs, no laser risk.
23. METiS Pharmaceutic
Strategy: AI design Nano carrier for drug ➔ Bioassay testing
Machine learning: from expert experience, trail-end-error
24. Erythra
Focus on diagnosis
Product: marker_KIT
Bad blood sample collections ➔ prepare homogenize ➔ create marker KIT
评论